Cancer Vaccine
Recombinant E. coli delivers antigen to human dendritic cells
Published in Vaccine Weekly, August 27th, 2003
According to a study from England, "The generation of tumor-specific cytotoxic T-lymphocyte (CTL) responses is the primary focus in the design of immunotherapeutic cancer vaccines. We have recently demonstrated generation of ovalbumin (OVA)-specific CTLs and tumor-protection in a murine tumor model using vaccination with dendritic cells (DCs) pulsed with E. coli expressing listeriolysin O (LLO) and OVA as a model antigen."
"In this system, paraformaldehyde fixation of E. coli/LLO provided an additional safety feature without...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2003-08-27)
More Articles from Vaccine Weekly
- DNA Vaccine
Technical and regulatory hurdles for DNA vaccines still remain - Vaccine Development
Genomic technologies aid rational antibacterial vaccine design - Cancer Vaccine
Cancer vaccines need to increase immune response to carbohydrate antigens - HIV/AIDS Vaccine
Lipopeptide MALP-2 effective adjuvant for mucosal delivery of HIV-1 protein - Virology Vaccine
Traditional and novel approaches to flavivirus vaccines reviewed - AIDS Prevention
$13 million grant puts new herpes-based AIDS vaccine on fast track - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
